Safety and Health Intervention Project
This trial is active, not recruiting.
|Conditions||drug overdose, opioid related disorders|
|Treatment||therapist-led brief intervention (tbi)|
|Sponsor||University of Michigan|
|Start date||October 2014|
|End date||February 2017|
|Trial size||139 participants|
|Trial identifier||NCT02152397, 1R34DA035331-01A1|
Use of opioid medications for treatment of pain has increased greatly in the U.S., with the average quantity of prescribed opioids increasing 700% in a decade, from ~100 morphine milligram equivalents (MME) per person to ~700 MME per person from 1997 to 2007. There have been concurrent increases in opioid-related adverse outcomes, such as extramedical use, opioid use disorders, and overdose. As a result, there were more unintentional poisoning deaths than deaths due to motor vehicle crashes among adults in 2010 (32,723 vs. 32,640). Additionally, the number of Americans seeking treatment for opioid use disorders has increased; in SAMHSA's Treatment Episode Data Set, prescription opioids were the primary substance of abuse for 142,782 individuals in 2009, compared to 22,637 in 1999, a 530% increase.
The specific aims of this project are to: (1) Refine a motivational enhancement prevention intervention for prescription opioid overdose risk reduction and improved witnessed overdose response for at-risk patients in addictions treatment; (2) Conduct a pilot randomized controlled trial comparing the prescription opioid overdose prevention intervention to a supportive educational control condition for patients in addictions treatment in order to: (a) obtain information about the feasibility of randomized controlled procedures; and (b) determine the distribution and variability of the primary (overdose risk behaviors) and mediating/secondary (witnessed overdose response, self-efficacy to reduce overdose risk, knowledge of overdose risk factors and symptom recognition) outcomes; and (3) Determine the distribution and variability in changes in HIV risk behaviors (e.g., reductions in injection of prescription opioids) over follow-up.
|Intervention model||parallel assignment|
Overdose risk behavior
time frame: Change over time (3- and 6-month post-baseline)
HIV risk behavor
time frame: Change over time (3- and 6-months post-baseline)
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients 18 and older in treatment at CPI - able to provide informed consent. Exclusion Criteria: - acute suicidality - psychiatric condition that precludes participation in the intervention - inability to speak and understand English - inability to give informed, voluntary, written consent for any reason
|Official title||Developing a Prescription Opioid Overdose Prevention Intervention in Addictions Treatment|
|Principal investigator||Amy Bohnert, PhD|
Call for more information